

Eligible patients aged 18 or above with type 2 diabetes between Nov 2012 and Dec 2018
(n=362,937)

New prescription of SGLT2i
(n=25,507)

New prescription of DPP4i
(n=33,553)

Exclusion of patients:

- With a prescription of SGLT2i or DPP4i in the 12 months period prior to the index (n=10,507)
- With a diagnosis of type 1 diabetes, secondary diabetes before index (n=385)
- With a diagnosis of gestational diabetes in the 12 months period prior to index date (n=4)
- With a diagnosis of end stage renal disease before index (n=8)
- With a diagnosis of gout before index (n=986)

Exclusion of patients:

- With a prescription of SGLT2i or DPP4i in the 12 months period prior to the index (n=96)
- With a diagnosis of type 1 diabetes, secondary diabetes before index (n=470)
- With a diagnosis of gestational diabetes in the 12 months period prior to index date (n=0)
- With a diagnosis of end stage renal disease before index (n=196)
- With a diagnosis of gout before index (n=3,365)

SGLT2i cohort
(n=13,617)

DPP4i Cohort
(n=29,426)

For the intention to treat analysis, follow-up ends at the earliest of:

1. Patient death
2. Patient transfer out of practice
3. End of practice data collection
4. Study end date
5. Development of AMD

Median Follow-Up (IQR) – 1.74 (0.78-3.07)

For the on treatment analysis, follow-up ends at the earliest of

1. Above scenarios
2. Discontinuation of exposure drug of interest
3. Switch to comparator drug

Median Follow-Up (IQR) – 1.12 (0.50-2.22)